Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

(2022) Rana Abdelnabi et al.   ANTIVIRAL RESEARCH

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

(2022) Wanwisa Dejnirattisai et al.   CELL

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

(2022) Elisabetta Cameroni et al.   NATURE

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

(2022) Peter J. Halfmann et al.   NATURE

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

(2022) Guillaume Beaudoin-Bussières et al.   Cell Reports

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

(2021) Rita E. Chen et al.   NATURE MEDICINE

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

(2021) Irfan Ullah et al.   IMMUNITY

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

(2021) Laura A. VanBlargan et al.   IMMUNITY

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

(2021) Rachel Yamin et al.   NATURE

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

(2021) Rita E. Chen et al.   NATURE

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

(2021) Florian A. Lempp et al.   NATURE

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

(2021) Jinhui Dong et al.   Nature Microbiology

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

(2020) Ruochen Zang et al.   Science Immunology

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

Growth, detection, quantification, and inactivation of SARS-CoV-2

(2020) James Brett Case et al.   VIROLOGY

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

(2019) Kevin O. Saunders   Frontiers in Immunology

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

(2018) Erica Ollmann Saphire et al.   CELL

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

(2018) Bronwyn M. Gunn et al.   Cell Host & Microbe

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

(2017) Thomas D. Goddard et al.   PROTEIN SCIENCE

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

(2016) David J. DiLillo et al.   JOURNAL OF CLINICAL INVESTIGATION

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural characterization of a human Fc fragment engineered for lack of effector functions

(2008) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY